SEATTLE, April 11, 2023 (GLOBE NEWSWIRE) — Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, announced today that four Trudhesa (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) abstracts have been selected to be presented at the…Read More
Impel Pharmaceuticals to Present Data on Trudhesa Nasal Spray for Treatment of Acute Migraine at 2023 American Academy of Neurology Annual Meeting
